April 1, 2022 7:42am

Jobs report for March …

News: Sage Therapeutics (SAGE +$2.63 or +7.95% pre-open) data from the P2 LUMINARY Study showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD).

Pre-open indications: 4 SELLs, 5 BUYs and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.50% (+172 points), S&P futures are UP +0.48% (+22 points) and NASDAQ futures are +0.54% (+80 points)

 

Stock futures rose early Friday seemingly optimistic as a new quarter of initiated and a worrying bond market recession indicator,

European markets inched higher coming off their first losing quarter in two years,

Asia-Pacific Markets declined following overnight losses and a private survey showed Chinese manufacturing activity shrank in March as the country battles its most severe Covid-19 outbreak since the onset of the pandemic.

 

Henry’omics:

Indexes retreated for the 2nd straight session; the Nasdaq has stopped just short of its 200-day line while the Dow fell back below that level and the S&P 500 moved back toward it.

All three major averages posted their worst quarter since March 2020. The Dow and S&P 500 declined 4.6% and 4.9% respectively during the period, and the Nasdaq dropped more than 9%. Stocks did stage a late-quarter comeback in March however after sharp declines from rising interest rates and inflation marked the first part of the year. <CNBC>

The 2-year and 10-year Treasury yields inverted for the first time since 2019. For some investors, it’s a signal that the economy is headed for a possible recession, though the inverted yield curve does not predict exactly when it will happen and history shows it could be more than a year away or longer.

Economic data Docket: jobs report, ISM manufacturing index and the construction spending report

·         “A strong jobs report Friday could give the Fed more confidence to keep its aggressive rate-hiking plan in place this year to stifle inflation without fear of slowing the economy too much.”

·         Economists expect that about 490,000 jobs were added in March, according to the consensus estimate, following a 678,000 payrolls addition in February. The unemployment rate is expected to fall to 3.7% from 3.8%.” <CNBC>

 

RegMed Investors’ (RMi) closing bell: “struggling for direction with fading optimism as March and Q1 end. Depressed momentum is linked inextricably to volatility, headline risks and an option expiration Thursday” … https://www.regmedinvestors.com/articles/12369

Ebb and flow –

Q2/22 – starts today, Friday

Q1/22:

·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  (VSTM, BCLI and ADVM) 34 total to date

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …

Maintaining BUY, some oversold that are poised to appreciate:

Agenus (AGEN) closed down -$0.16 after Wednesday’s -$0.07 with a positive +$0.04 or +1.63% pre-open indication,

Caribou Biosciences (CRBU) closed down -$0.07 after Wednesday’s -$0.20, Tuesday’s +0.11 after Monday’s +$0.12 with a positive +$0.12 or +1.31% pre-open indication.

Beam Therapeutics (BEAM) closed down -$2.15 after Wednesday’s -$2.57 and Tuesday’s +$2.97 with a +$0.80 or +1.40% pre-open indication.

CRISPR Therapeutics (CRSP) closed down -$1.31 after Wednesday’s -$1.87, Tuesday’s +$3.12 and Monday’s +$0.69 with a positive +$0.23 or +0.37% pre-open indication.

BUY with news:

Sage therapeutics (SAGE) closed down -$1.18 to $33.10 with a positive +$2.63 or +7.95% pre-open indication on news of data from the P2 LUMINARY Study that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD).

 

SELL:

Global Blood Therapeutics (GBT) closed down -$0.31 after Wednesday’s -$0,54 with a negative -$0.42 or -1.21% pre-open indication

Maintaining SELL:

Fate Therapeutics (FATE) closed down -$1.09 after Wednesday’s -$2.08 after Tuesday’s +$3.94 with a negative -$0.07 or -0.18% pre-open indication.

SELL into Strength:

Ionis Pharmaceuticals (IONS) closed up +$1.35 to $37.014 after Wednesday’s $35.69, Tuesday’s $36.46, Monday’s $35.88 and last Friday’s $36.67 with a -$0.11 or -0.30% pre-open indication

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed down -$0.10 with 124 shares traded after Wednesday’s +$0.50 with 3,932 shares traded, Tuesday’s -$0.50 with 3,330 shares traded, Monday’s +$0.26 to $5.00 with 13,012 shares traded and last Friday’s +$0.44 with 1,978 shares traded. WHY BUY these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?

·         Earnings today, WHAT will be said and … can be BELIEVED?

 

The BOTTOM LINE:starting a new month and quarter (Q2) ...

What goes down, eventually bounces from being oversold.

The week says it all …

·         Thursday closed negative with 9 incliners, 24 decliners and 2 flats

·         Wednesday closed negative with 7 incliners and 28 decliners

·         Tuesday closed positive with 32 incliners and 3 decliners

·         Monday closed negative with 13 incliners, 20 decliners and 2 flats

·         Friday closed negative with 7 incliners and 28 decliners

Reiterating, “An odd quote that caught my eye and some feelings, “To paraphrase the Rolling Stones, you can't always get what you want, but sometimes you get what you need.”

Share pricing ascension or appreciation!

Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.